有乳腺癌病史的炎症性肠病患者发生新发癌症的风险:一项多中心队列研究
该多中心回顾性研究纳入207例有乳腺癌病史的炎症性肠病患者,评估后续IBD治疗与新发癌症(复发或新发)的关系。中位随访71个月,42例(20%)出现新发癌症,其中34例为乳腺癌复发。未治疗组调整发病率10.2/1000人年,暴露组28.9/1000人年(P=0.0519),无癌症生存率无显著差异(P=0.4796)。结论:除已知乳腺癌不良预后因素外,未发现IBD治疗显著增加新发乳腺癌风险。
要点
- 有乳腺癌病史的IBD患者中,20%(42/207)出现新发癌症,其中34例为乳腺癌复发。
- 未治疗组调整发病率10.2/1000人年,暴露组28.9/1000人年(P=0.0519)。
- 治疗组与对照组无癌症生存率无显著差异(P=0.4796)。
核心结论
- 除已知的乳腺癌不良预后因素外,未发现IBD治疗与新发乳腺癌风险存在统计学显著增加。
研究设计与样本
- 多中心回顾性研究,纳入207例有乳腺癌病史的连续IBD患者,纳入日期为指数恶性肿瘤诊断日。
- 随访从癌症诊断持续至新发癌症发生,中位随访71个月(四分位距34-148)。
主要发现
- 207例患者中位病程13年(四分位距6-21),一线治疗中位间隔28个月(四分位距7-64)。
- 一线治疗中传统免疫抑制剂占19.3%,抗肿瘤坏死因子占19.8%,维得利珠单抗占7.2%,乌司奴单抗占1.9%。
- 随访期间共观察42例(20%)新发癌症,其中34例为乳腺癌复发。
- 未治疗组调整发病率10.2/1000人年(95%CI 6.0-16.4),暴露组28.9/1000人年(95%CI 11.6-59.6),P=0.0519。
- 治疗组与对照组无癌症生存率无显著差异(P=0.4796)。
关键数值与推荐
- 多因素分析中与新发癌症相关的因素包括T4d分期(P=0.036)、三阴性肿瘤(P=0.016)和随访不足71个月(P=0.005)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Breast cancer is the most common malignancy observed in patients with inflammatory bowel diseases (IBD). The aim of our study was to evaluate incident cancer rate (recurrence or new-onset cancer) in a cohort of patients with IBD with a history of breast cancer according to the subsequent IBD treatment provided. METHODS: A multicenter retrospective study included consecutive patients with IBD with prior breast cancer. The inclusion date corresponded to the diagnosis of index malignancy. Follow-up lasted from cancer diagnosis until the occurrence of incident cancer. RESULTS: Among 207 patients included (median disease duration, 13 years [interquartile range, 6-21]), first-line treatment (median interval of 28 months [interquartile range, 7-64]) was a conventional immunosuppressant in 19.3% of patients, anti-tumor necrosis factor in 19.8%, vedolizumab in 7.2%, and ustekinumab in 1.9%. After a median follow-up of 71 months (interquartile range, 34-148), 42 (20%) incident cancers were observed (34 breast cancer recurrences). Adjusted incidence rates per 1000 person-years were 10.2 (95% confidence interval, 6.0-16.4) for the untreated arm and 28.9 (95% confidence interval, 11.6-59.6) for exposed patients (P = .0519). There was no significant difference between treated patients and control subjects regarding incident cancer-free survival rates (P = .4796). In multivariable analysis, factors associated with incident cancer were stage T4d (P = .036), triple negative tumor (P = .016), and follow-up of less than 71 months (P = .005). CONCLUSIONS: We did not find a statistically significant increase in incident breast cancer related to IBD treatment beyond the already known poor prognostic factors of breast cancer.
引用
- Le Cosquer G, Kirchgesner J, Gilletta De Saint Joseph C, et al. Risk of Incident Cancer in Patients With Inflammatory Bowel Disease With Prior Breast Cancer: A Multicenter Cohort Study. Clin Gastroenterol Hepatol. 2024. PMID: 39505240. doi:10.1016/j.cgh.2024.09.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。